Gambogic Acid Is a Tissue-Specific Proteasome Inhibitor In Vitro and In Vivo

56Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Gambogic acid (GA) is a natural compound derived from Chinese herbs that has been approved by the Chinese Food and Drug Administration for clinical trials in cancer patients; however, its molecular targets have not been thoroughly studied. Here, we report that GA inhibits tumor proteasome activity, with potency comparable to bortezomib but much less toxicity. First, GA acts as a prodrug and only gains proteasome-inhibitory function after being metabolized by intracellular CYP2E1. Second, GA-induced proteasome inhibition is a prerequisite for its cytotoxicity and anticancer effect without off-targets. Finally, because expression of the CYP2E1 gene is very high in tumor tissues but low in many normal tissues, GA could therefore produce tissue-specific proteasome inhibition and tumor-specific toxicity, with clinical significance for designing novel strategies for cancer treatment. © 2013 The Authors.

Cite

CITATION STYLE

APA

Li, X., Liu, S., Huang, H., Liu, N., Zhao, C., Liao, S., … Liu, J. (2013). Gambogic Acid Is a Tissue-Specific Proteasome Inhibitor In Vitro and In Vivo. Cell Reports, 3(1), 211–222. https://doi.org/10.1016/j.celrep.2012.11.023

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free